TY - JOUR
T1 - Significance of 1khz pure-tone threshold in acute low-frequency sensorineural hearing loss
AU - Lee, Chi Kyou
AU - Lee, Jong Bin
AU - Park, Kye Hoon
AU - Lee, Ho Yun
AU - Choi, Mi Jin
AU - Ban, Wonwoo
AU - Choi, Seong Jun
N1 - Publisher Copyright:
© 2018, Otology & Neurotology, Inc.
PY - 2018
Y1 - 2018
N2 - Objectives: To analyze risk factors for acute low-frequency hearing loss (ALFHL), and compare treatment outcomes in the presence or absence of such risk factors. Study Design: A case series featuring retrospective chart review. Setting: An academic university hospital. Patients: We included 170 ALFHL patients without vertigo. All of the patients received one of four treatments: low-dose steroid (LD-steroid), high-dose steroid (HD-steroid), LD-steroid and diuretics (LD-combination therapy), and ITDI (intratympanic dexamethasone injection) and diuretics (ITDI-combination therapy). To identify risk factors, we reviewed the clinical features of patients such as age, sex, chief complaint, accompanying symptoms, diabetes, hypertension, time from disease onset, the extent of hearing loss, treatment methods, and 1kHz involvement. Interventions: ALFHL was diagnosed based on the average hearing loss >30dB at 250 and 500Hz. Results: The overall rates of hearing recovery were 70–80% in the four treatment groups. In terms of the prognosis of ALFHL patients, we found that a longer time from disease onset and 1 kHz involvement were independent risk factors for poor prognosis. In addition, we compared treatment outcomes of four treatment methods in the presence or absence of risk factors. In ALFHL patients with risk factors, we found statistically significant differences (p = 0.042) among treatment methods; effectiveness ranged in the order if ITDI-combination therapy, LD-combination therapy, HD-steroid, and LD-steroid. Conclusions: Risk factors for poor hearing recovery in ALFHL included longer symptom duration and 1 kHz involvement. In ALFHL with such risk factors, combination therapy was more effective than oral steroid therapy.
AB - Objectives: To analyze risk factors for acute low-frequency hearing loss (ALFHL), and compare treatment outcomes in the presence or absence of such risk factors. Study Design: A case series featuring retrospective chart review. Setting: An academic university hospital. Patients: We included 170 ALFHL patients without vertigo. All of the patients received one of four treatments: low-dose steroid (LD-steroid), high-dose steroid (HD-steroid), LD-steroid and diuretics (LD-combination therapy), and ITDI (intratympanic dexamethasone injection) and diuretics (ITDI-combination therapy). To identify risk factors, we reviewed the clinical features of patients such as age, sex, chief complaint, accompanying symptoms, diabetes, hypertension, time from disease onset, the extent of hearing loss, treatment methods, and 1kHz involvement. Interventions: ALFHL was diagnosed based on the average hearing loss >30dB at 250 and 500Hz. Results: The overall rates of hearing recovery were 70–80% in the four treatment groups. In terms of the prognosis of ALFHL patients, we found that a longer time from disease onset and 1 kHz involvement were independent risk factors for poor prognosis. In addition, we compared treatment outcomes of four treatment methods in the presence or absence of risk factors. In ALFHL patients with risk factors, we found statistically significant differences (p = 0.042) among treatment methods; effectiveness ranged in the order if ITDI-combination therapy, LD-combination therapy, HD-steroid, and LD-steroid. Conclusions: Risk factors for poor hearing recovery in ALFHL included longer symptom duration and 1 kHz involvement. In ALFHL with such risk factors, combination therapy was more effective than oral steroid therapy.
KW - Hearing loss
KW - Low tone
KW - Prognosis
KW - Sudden hearing loss
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85056567912&partnerID=8YFLogxK
U2 - 10.1097/MAO.0000000000002023
DO - 10.1097/MAO.0000000000002023
M3 - Article
C2 - 30444841
AN - SCOPUS:85056567912
SN - 1531-7129
VL - 39
SP - e950-e955
JO - Otology and Neurotology
JF - Otology and Neurotology
IS - 10
ER -